14 Oct 2025 | 5 Mins Read
Natco Pharma shares fall 3.5% as SC rules on Roche plea
Flipitmoney
The Supreme Court agreed to urgently list Roche's plea to halt Natco Pharma's launch of the spinal muscular atrophy (SMA) drug Risdiplam. Natco Pharma shares fell 3.5% on October 14. The Delhi High Court previously allowed Natco to sell the drug in India, paving the way for its generic launch at Rs 15,900 MRP, with potential discounts for deserving patients.